{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T13:43:21Z","timestamp":1783518201069,"version":"3.55.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004608","name":"Jiangsu Province Natural Science Foundation","doi-asserted-by":"publisher","award":["BK20230017"],"award-info":[{"award-number":["BK20230017"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012246","name":"Priority Academic Program Development of Jiangsu Higher Education Institutions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172683"],"award-info":[{"award-number":["82172683"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82303710"],"award-info":[{"award-number":["82303710"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008868","name":"Jiangsu Province Department of Science and Technology","doi-asserted-by":"publisher","award":["BE2022807"],"award-info":[{"award-number":["BE2022807"]}],"id":[{"id":"10.13039\/501100008868","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007452","name":"Wu Jieping Medical Foundation","doi-asserted-by":"publisher","award":["320.6750.2023-18-1"],"award-info":[{"award-number":["320.6750.2023-18-1"]}],"id":[{"id":"10.13039\/100007452","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007452","name":"Wu Jieping Medical Foundation","doi-asserted-by":"publisher","award":["320.6750.2022-19-90"],"award-info":[{"award-number":["320.6750.2022-19-90"]}],"id":[{"id":"10.13039\/100007452","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.eclinm.2025.103376","type":"journal-article","created":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T17:51:32Z","timestamp":1752947492000},"page":"103376","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["De-escalated neoadjuvant nab-paclitaxel combined with pyrotinib and trastuzumab in intrinsic HER2-enriched breast cancer (NJMU-BC01): a multicenter, single-arm, phase 2 trial"],"prefix":"10.1016","volume":"86","author":[{"given":"Hong","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyao","family":"Zha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingduo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Zha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiansong","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1220-6797","authenticated-orcid":false,"given":"Wenbin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2025.103376_bib1","article-title":"Genomic classification of HER2-positive patients with 80-gene and 70-gene signatures identifies diversity in clinical outcomes with HER2-targeted neoadjuvant therapy","volume":"6","author":"Whitworth","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103376_bib2","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/s41571-019-0299-9","article-title":"Towards personalized treatment for early stage HER2-positive breast cancer","volume":"17","author":"Goutsouliak","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"10.1016\/j.eclinm.2025.103376_bib3","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju152","article-title":"Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer","volume":"106","author":"Prat","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"21","key":"10.1016\/j.eclinm.2025.103376_bib4","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1158\/0008-5472.CAN-23-4066","article-title":"Molecular characterization and classification of HER2-positive breast cancer inform tailored therapeutic strategies","volume":"84","author":"Li","year":"2024","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103376_bib5","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1200\/JCO.2015.62.1268","article-title":"Molecular heterogeneity and response to neoadjuvant human epidermal growth factor receptor 2 targeting in CALGB 40601, a randomized phase III trial of paclitaxel plus trastuzumab with or without lapatinib","volume":"34","author":"Carey","year":"2016","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103376_bib6","doi-asserted-by":"crossref","first-page":"e877","DOI":"10.1093\/oncolo\/oyae047","article-title":"Comparison of the response to neoadjuvant therapy between immunohistochemistry HER2 (3+) and HER2 (2+)\/ISH+ early-stage breast cancer: a retrospective multicenter cohort study","volume":"29","author":"Jiao","year":"2024","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103376_bib7","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/jnci\/djz042","article-title":"HER2-Enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade","volume":"112","author":"Prat","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eclinm.2025.103376_bib8","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ejps.2017.01.021","article-title":"Discovery and development of pyrotinib: a novel irreversible EGFR\/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer","volume":"110","author":"Li","year":"2017","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.eclinm.2025.103376_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105379","article-title":"Pyrotinib and trastuzumab combination treatment synergistically overcomes HER2 dependency in HER2-positive breast cancer: insights from the PHILA trial","volume":"109","author":"Liu","year":"2024","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103376_bib10","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1186\/s12916-022-02708-3","article-title":"Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial","volume":"20","author":"Wu","year":"2022","journal-title":"BMC Med"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103376_bib11","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/S1470-2045(21)00122-4","article-title":"Chemotherapy de-escalation using an (18)F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial","volume":"22","author":"Perez-Garcia","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103376_bib12","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1470-2045(17)30716-7","article-title":"Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial","volume":"19","author":"Hurvitz","year":"2018","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.eclinm.2025.103376_bib13","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/annonc\/mdx494","volume":"28","author":"Nitz","year":"2017","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103376_bib14","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S1470-2045(15)00542-2","article-title":"Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial","volume":"17","author":"Untch","year":"2016","journal-title":"Lancet Oncol"},{"issue":"25","key":"10.1016\/j.eclinm.2025.103376_bib15","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1200\/JCO.18.01842","article-title":"NAB-paclitaxel improves disease-free survival in early breast cancer: GBG 69-GeparSepto","volume":"37","author":"Untch","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2025.103376_bib16","article-title":"Efficacy comparisons of solvent-based paclitaxel, liposomal paclitaxel, nanoparticle albumin-bound paclitaxel, and docetaxel after neoadjuvant systemic treatment in breast cancer","volume":"54","author":"Zhang","year":"2023","journal-title":"Nanomedicine"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103376_bib17","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1200\/JCO.21.02019","article-title":"Outcome of patients with an ultralow-risk 70-gene signature in the MINDACT trial","volume":"40","author":"Lopes Cardozo","year":"2022","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103376_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100756","article-title":"Performance characteristics of the BluePrint(R) breast cancer diagnostic test","volume":"13","author":"Mittempergher","year":"2020","journal-title":"Transl Oncol"},{"issue":"8","key":"10.1016\/j.eclinm.2025.103376_bib19","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa1602253","article-title":"70-Gene signature as an aid to treatment decisions in early-stage breast cancer","volume":"375","author":"Cardoso","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103376_bib20","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/gcc.23014","article-title":"MammaPrint and BluePrint comprehensively capture the cancer hallmarks in early-stage breast cancer patients","volume":"61","author":"Haan","year":"2022","journal-title":"Genes Chromosomes Cancer"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103376_bib21","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.annonc.2024.10.018","article-title":"Pathologic complete response (pCR) rates for patients with HR+\/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial","volume":"36","author":"Huppert","year":"2025","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.eclinm.2025.103376_bib22","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1093\/annonc\/mdw262","article-title":"Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial","volume":"27","author":"Dieci","year":"2016","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103376_bib23","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1001\/jamaoncol.2016.3824","article-title":"RNA sequencing to predict response to neoadjuvant anti-HER2 therapy: a secondary analysis of the NeoALTTO randomized clinical trial","volume":"3","author":"Fumagalli","year":"2017","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103376_bib24","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/annonc\/mdx647","article-title":"A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade","volume":"29","author":"Nuciforo","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2025.103376_bib25","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ctrv.2017.04.005","article-title":"Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: a meta-analysis of randomized controlled trials","volume":"57","author":"Solinas","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.eclinm.2025.103376_bib26","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ejca.2022.01.022","article-title":"Pathological response and predictive role of tumour-infiltrating lymphocytes in HER2-positive early breast cancer treated with neoadjuvant pyrotinib plus trastuzumab and chemotherapy (Panphila): a multicentre phase 2 trial","volume":"165","author":"Liu","year":"2022","journal-title":"Eur J Cancer"},{"issue":"17_suppl","key":"10.1016\/j.eclinm.2025.103376_bib27","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA500","article-title":"De-escalated neoadjuvant taxane plus trastuzumab and pertuzumab with or without carboplatin in HER2-positive early breast cancer (neoCARHP): a multicentre, open-label, randomised, phase 3 trial","volume":"43","author":"Gao","year":"2025","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103376_bib28","doi-asserted-by":"crossref","first-page":"200","DOI":"10.21037\/atm-22-4030","article-title":"Neoadjuvant therapy with vs. without anthracyclines for HER2-positive breast cancer: a systematic review and meta-analysis","volume":"11","author":"Zhu","year":"2023","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.eclinm.2025.103376_bib29","doi-asserted-by":"crossref","DOI":"10.1177\/11795549231195293","article-title":"The value of neoadjuvant anthracycline-based regimens for HER2-positive breast cancer: a systematic review and meta-analysis including 1366 patients","volume":"17","author":"Ding","year":"2023","journal-title":"Clin Med Insights Oncol"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103376_bib30","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","article-title":"Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)","volume":"24","author":"Schneeweiss","year":"2013","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103376_bib31","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13058-022-01587-z","article-title":"Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE)","volume":"25","author":"de Haas","year":"2023","journal-title":"Breast Cancer Res"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103376_bib32","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13058-023-01664-x","article-title":"BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer","volume":"25","author":"Liefaard","year":"2023","journal-title":"Breast Cancer Res"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103376_bib33","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1093\/annonc\/mdx048","article-title":"Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy-results from the ACOSOG Z1041 (Alliance) trial","volume":"28","author":"Lesurf","year":"2017","journal-title":"Ann Oncol"},{"issue":"18","key":"10.1016\/j.eclinm.2025.103376_bib34","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1158\/1078-0432.CCR-24-0464","article-title":"HER2DX genomic assay in HER2-positive early breast cancer treated with trastuzumab and pertuzumab: a correlative analysis from the PHERGain phase II trial","volume":"30","author":"Llombart-Cussac","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eclinm.2025.103376_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103801","article-title":"Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer","volume":"75","author":"Prat","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.eclinm.2025.103376_bib36","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4137\/BMI.S6184","article-title":"Biological functions of the genes in the mammaprint breast cancer profile reflect the hallmarks of cancer","volume":"5","author":"Tian","year":"2010","journal-title":"Biomark Insights"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103376_bib37","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1586\/erm.09.32","article-title":"MammaPrint 70-gene signature: another milestone in personalized medical care for breast cancer patients","volume":"9","author":"Slodkowska","year":"2009","journal-title":"Expert Rev Mol Diagn"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103376_bib38","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(24)00581-3","article-title":"De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial","volume":"26","author":"Chen","year":"2025","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103376_bib39","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s10549-020-06075-6","article-title":"Concordance of the 21-gene assay between core needle biopsy and resection specimens in early breast cancer patients","volume":"186","author":"Qi","year":"2021","journal-title":"Breast Cancer Res Treat"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025003086?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025003086?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T03:37:55Z","timestamp":1772768275000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537025003086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":39,"alternative-id":["S2589537025003086"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103376","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"De-escalated neoadjuvant nab-paclitaxel combined with pyrotinib and trastuzumab in intrinsic HER2-enriched breast cancer (NJMU-BC01): a multicenter, single-arm, phase 2 trial","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103376","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103376"}}